belinostat (beleodaq) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Belinostat is a hydroxamate-type histone deacetylase inhibitor indicated for the treatment of relapsed or refractory peripheal T-cell lymphoma. The compound received orphan drug designation for the treatment of malignant thymomas. Acting on a histone deacetylase Belinostat causes the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. PXD101 has been shown in preclinical studies to have the potential to treat a wide range of solid and hematologic malignancies either as a monotherapy or in combination with other active agents, and both an oral and intravenous formulation of the drug are being evaluated in clinical trials.   NCATS

  • SMILES: ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC2=CC=CC=C2
  • Mol. Mass: 318.348
  • ALogP: 2.01
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-propenamide, n-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)- | belecodaq | beleodaq | belinostat | pxd101 | pxd-101


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue